Experimental models of neuroprotection relevant to multiple sclerosis

Neurology

Volumn 68, Issue 22 SUPPL. 3, 2007, Pages

  Yong, V W ^a   Giuliani, F ^b   Xue, M ^a   Bar Or, A ^c   Metz, L M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GELATINASE B; IMMUNOGLOBULIN; MINOCYCLINE; NATALIZUMAB;

APOPTOSIS; BRAIN DAMAGE; CELL KILLING; CONFERENCE PAPER; EXPERIMENTAL MODEL; HUMAN; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; CELL DEATH; DISEASE MODELS, ANIMAL; HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS;

EID: 34249809137     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000275230.20635.72     Document Type: Conference Paper

References (50)

1. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-399.
2. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
3. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
4. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650-653.
5. DeStefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70.
6. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999;5:48-57.
7. + T cells in multiple sclerosis: a new target for therapy? Brain 2005;128(pt 8):1747-1763.
8. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000;157:267-276.
9. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-2212
10. Giuliani F, Fu SA, Metz LM, Yong VW. Effective combination of minocycline and interferon-β in a model of multiple sclerosis. J Neuroimmunol 2005;165:83-91.
11. Giuliani F, Goodyer CG, Antel JP, Yong VW. Vulnerability of human neurons to T cell-mediated cytotoxicity. J Immunol 2003;171:368-379.
12. Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006;18:670-675.
13. Steinman L. A brief history of Th17, the first major revision in the Th1/Th2 hypotheses of T cell-mediated tissue damage. Nature Med 2007;13:139-145.
14. Wang T, Allie R, Conant K, et al. Granzyme B mediates neurotoxicity through G-protein-coupled receptor. FASEB J 2006;20:1209-1211.
15. Murray PD, McGavern DB, Lin X, et al. Perforin-dependent neurologic injury in a viral model of multiple sclerosis. J Neurosci 1998;18:7306-7314.
16. Medana I, Li Z, Flügel A, Tschopp J, Wekerle H, Neumann H. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity. J Immunol 2001;167:674-681.
17. Aktas O, Smorodchenko A, Brocke S, et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005;46:421-432.
18. Kipnis J, Yoles E, Porat Z, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 2000;97:7446-7451.
19. Ziemssen T, Kumpfel T, Klinkert WEF, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 2002;125:2381-2391.
20. Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotropic factor. J Neurol Sci 2003;215:37-44.
21. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005;4:567-575.
22. Skihar V, Silva C, Yong VW. The production of multiple neurotrophic factors by glatiramer acetate-specific T cells facilitates the generation of oligodendrocytes. Mult Scler 2006;12(suppl 1):S54. Abstract.
23. Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA 2001;98:3398-3403.
24. Angelov DN, Waibel S, Guntinas-Lichius O, et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2003;100:4790-4795.
25. Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen D. Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res 2003;47:201-207.
26. Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2004;101:9435-9440.
27. Frenkel D, Maron R, Burt DS, Weiner H. Nasal vaccination with a proteasome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease. J Clin Invest 2005;115:2423-2433.
28. Janke AD, Giuliani F, Yong VW. IVIg attenuates T cell-mediated killing of human neurons. J Neuroimmunol 2006;177:181-188.
29. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nature Rev Neurosci 2005;6:931-944.
30. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nature Rev Neurosci 2001;2:502-511.
31. Correale J, Molinas MMB. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol 2003;140:198-209.
32. Xue M, Hollenberg M, Yong VW. Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. J Neurosci 2006;26:10281-10291.
33. Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH. T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 2001;124:2203-2214.
34. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004;3:744-751.
35. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002;125:1297-1308.
36. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51:215-223.
37. Wells JEA, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003;126:1628-1637.
38. Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol 2005;158:213-221.
39. Yong VW. Prospects for neuroprotection in multiple sclerosis. Front Biosci 2004;9:864-872.
40. Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2004;55:756. Letter.
41. Zabad RK, Metz LM, Todoruk TR, et al. Clinical response to minocycline in MS is accompanied by immune changes. Mult Scler 2006 (in press).
42. Lappe-Siefke C, Goebbels S, Gravel M, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nature Genet 2003;33:366-374.
43. Kalhers NF, Barkhof F, Bergers E, Van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI parameters in patients with progressive multiple sclerosis: a pilot study. Mult Scler 2002;8:532-533.
44. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005;233:3-13.
45. Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 2004;10:93-98.
46. Kaminska B, Gaweda-Walerych K, Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants - facts and hypotheses. J Cell Mol Med 2004;8:45-58.
47. Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 2004;55:607-616.
48. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nature Med 2000;6:67-70.
49. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003;126(Pt 10):2191-2202.
50. Farrell R, Heaney D, Giovannoni G. Emerging therapies in multiple sclerosis. Expert Opin Emerg Drugs 2005;10:797-816.